HIFEM Therapy for Health & Longevity - Quick Reference Sheet

HIFEM Therapy for Health & Longevity

Created on 09/11/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Forced magnetic muscle contractions improve pelvic floor weakness and leakage in women, and in men after prostate surgery — the firmest finding. Body-shaping claims are contested: small fat and muscle changes, possibly swelling. Deep fat, core strength, joint function and age-related muscle loss rest on single studies with no comparison group, or on animals. Harms are minimal; most research is industry-linked. (Full Review)

Protocol

Standard body-contouring course
4 × 30-minute sessions
Spaced 2–3 days apart over 2 weeks, intensity raised to the maximum tolerable level, with imaging or circumference assessment at 1 and 3 months
Standard continence course
6 × 28-minute sessions
Seat-based, twice weekly across 3 weeks, fully clothed
Best time of day
No trial has compared timing
Sessions are commonly scheduled on non-training days or at least several hours away from planned resistance work
Time to effect
Continence improvement
After the sixth session
Continues improving to 3 months
Sexual function
8 weeks
Between-group gains at 8 weeks versus pelvic floor training alone, and at 14 weeks versus sham
Imaging change
1 month
Measurable after a four-session course, peaks at 3 months; nothing is perceptible after a single session

Benefits

Contraindications
  • Cardiac pacemakers, implantable cardioverter-defibrillators, neurostimulators, cochlear implants, or any other implanted electronic device
  • Metal implants, surgical staples, drug pumps, or copper intrauterine devices within or adjacent to the treatment field
  • Pregnancy at any gestational age; the first 6 weeks after vaginal delivery and the first 3 months after cesarean delivery
  • Active malignancy in or adjacent to the treatment field, and any undiagnosed mass in that field
  • Epilepsy or any other seizure disorder
  • Decompensated heart failure (New York Heart Association Class IV), recent myocardial infarction within 90 days, or pulmonary insufficiency
  • Hemorrhagic disorder, or anticoagulation with an international normalized ratio above 3.5
  • Febrile illness, active skin infection, or open wound at the applicator site
  • Pelvic organ prolapse beyond stage 2, for the seat-based continence applicator
  • Botulinum toxin injected into the treatment field (same muscle group)
Key Interactions
  • Anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel, aspirin)
  • Muscle relaxants (baclofen, tizanidine, cyclobenzaprine)
  • Over-the-counter analgesics (ibuprofen, naproxen, acetaminophen)
  • Supplement interactions (creatine monohydrate, caffeine, beta-alanine)
  • Supplements with additive effects (creatine monohydrate, whey or leucine-rich protein, vitamin D)
  • Other interventions (resistance training, cryolipolysis, semaglutide and other GLP-1 agonists)

Risk & Side Effects

  • High: Treatment discomfort and post-session muscle soreness
  • Medium: Transient skin erythema and thermal injury with radiofrequency-combined devices
  • Low: Transient bowel and urinary symptoms with the seat applicator; menstrual cycle irregularity; applicator-site subcutaneous nodularity; displacement of resistance training for a small measured gain
  • Speculative: Rhabdomyolysis from supramaximal contraction; interference with implanted electronic or metal devices; long-term tendon and joint loading effects

Monitoring

Marker Target Why
Creatine kinase (CK) 60–150 U/L Detects muscle-fiber breakdown after supramaximal loading
Alanine aminotransferase (ALT) 10–19 U/L (women), 10–26 U/L (men) Confirms liver is unaffected by stacked sessions and by mobilized fatty acids
High-sensitivity C-reactive protein (hs-CRP) < 1.0 mg/L Baseline for the inflammation claimed to accompany fat-cell death, and a check that sessions are not driving a systemic response
Glycated hemoglobin (HbA1c) 5.0–5.4% Tracks whether any visceral-fat change translates into glucose control
Fasting insulin 2–5 µIU/mL The most responsive marker if visceral fat genuinely falls
Apolipoprotein B (ApoB) < 80 mg/dL Reference point for lipid shifts if adipose tissue is genuinely mobilized
Fat and muscle thickness at a fixed anatomical slice No established target — track the change from the individual's own baseline at an identical slice level and applicator landmark The only direct measure of what the treatment claims to do

Cadence: After the final session, then at 1 month, 3 months, and 6 to 12 months, with laboratory repeats only 24–48 hours after any stacked same-day schedule and at 3 months. Qualitative markers are tracked weekly during the course and at each follow-up.

Qualitative Assessment

  • Perceived core stability during loaded movements such as carries and planks
  • Leakage episodes and pad use recorded in a three-day diary rather than from recall
  • Post-session soreness intensity and how many days it lasts
  • Fit of clothing at the treated region, as a crude but honest circumference proxy
  • Joint stiffness and range of motion where extremities were treated
  • Sexual function and comfort, where the continence applicator was used